ResMed (RMD) Stock Forecast & Price Target

$239.89 +2.76 (+1.16%)

As of 01/17/2025 03:59 PM Eastern

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 14 Analyst Ratings

Sell
1

Hold
7

Buy
6

Based on 14 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 1 has given a sell rating, 7 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$233.09
-2.83% Downside

According to the 14 analysts' twelve-month price targets for ResMed, the average price target is $233.09. The highest price target for RMD is $283.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted downside of -2.83% from the current price of $239.89.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	7 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$233.09	$227.91	$218.18	$205.11
Forecasted Upside	-2.83% Downside	-3.95% Downside	-9.08% Downside	18.88% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.43	2.82	2.52
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-2.83% Downside	24,741.19% Upside	12.44% Upside
News Sentiment Rating	Positive News See Recent RMD News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/16/2025	The Goldman Sachs Group 3 of 5 stars	D. Thillainathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
1/10/2025	Piper Sandler 2 of 5 stars	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$252.00	+6.84%
12/13/2024	Stifel Nicolaus 4 of 5 stars		Initiated Coverage	Hold	$250.00	+3.09%
10/25/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$251.00 ➝ $266.00	+3.55%
10/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$224.00 ➝ $232.00	-9.68%
10/25/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/27/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$215.00	+9.88%
1/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$175.00 ➝ $180.00	-3.41%
1/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$160.00 ➝ $195.00	+7.32%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$180.00 ➝ $169.00	+21.82%
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%
1/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kaczor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:59 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 19, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. reported earnings per share of $2.20 for the latest quarter, surpassing analysts' expectations of $2.03, indicating strong financial performance and effective management.
The company achieved a revenue of $1.22 billion, exceeding the forecast of $1.19 billion, showcasing its ability to grow and capture market share in the medical equipment sector.
With a net margin of 23.15% and a return on equity of 25.53%, ResMed Inc. demonstrates efficient operations and profitability, which are attractive metrics for potential investors.
ResMed Inc. has declared a quarterly dividend of $0.53 per share, translating to an annualized dividend of $2.12 and a yield of 0.92%, providing a steady income stream for shareholders.
The current stock price is approximately $248.81, reflecting a positive market sentiment and potential for further appreciation based on recent analyst upgrades.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Insider selling activity has been noted, with significant shares sold by directors, which may raise concerns about their confidence in the company's future performance.
Despite recent positive earnings, the stock has received a mix of ratings, with one analyst issuing a sell rating, indicating potential volatility and differing opinions on its future value.
Institutional investors hold 54.98% of the company's stock, which can lead to increased volatility if large shareholders decide to sell their positions.
The company's payout ratio is currently at 28.08%, which, while sustainable, may limit the potential for future dividend increases if earnings do not grow significantly.
Recent analyst price targets vary, with some suggesting a target as low as $224.00, indicating uncertainty about the stock's future performance in the market.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $233.09, with a high forecast of $283.00 and a low forecast of $180.00.
: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There is currently 1 sell rating, 7 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
: According to analysts, ResMed's stock has a predicted downside of -2.83% based on their 12-month stock forecasts.
: ResMed has been rated by research analysts at KeyCorp, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, and The Goldman Sachs Group in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating for ResMed is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:RMD) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target